ABSTRACT
of topo II␤ Ϫ/Ϫ and topo II␤ ϩ/ϩ cells were carried out to establish whether the absence of topo II␤ caused drug resistance. Increased survival of topo II␤ Ϫ/Ϫ cells compared with topo II␤ ϩ/ϩ cells was observed after treatment with amsacrine (mAMSA) 
, methyl N-(4Ј-[9-acridinylamino]-2-methoxyphenyl) carbamate hydrochloride (AMCA), methyl N-(4Ј-[9-acridinylamino]-2-methoxyphenyl)carbamate
hydrochloride (mAMCA), mitoxantrone, and etoposide. These studies showed that topo II␤ Ϫ/Ϫ cells were significantly more resistant to mAMSA, AMCA, mAMCA, and mitoxantrone, than topo II␤ ϩ/ϩ cells, indicating that topo II␤ is an important target for the cytotoxic effects of these compounds.
Eukaryotic topoisomerase II (topo II) is an ATP-dependent nuclear enzyme that catalyzes changes in DNA topology. The reaction mechanism involves the passage of one DNA duplex through another by transiently cleaving a single DNA helix to create a DNA gate. During the cleavage reaction, a covalent enzyme-DNA intermediate is formed between a tyrosine residue of each topo II monomer and the 5Ј-phosphate group of the cleaved DNA. This covalent intermediate is known as a "cleavable complex" (Wang, 1996; Austin and Marsh, 1998) . Topo II has been implicated in a number of cellular processes, including DNA replication, recombination, and chromatin organization (Earnshaw et al., 1985; Chen et al., 1996; Wang, 1996) . In addition, it is an important cellular target for a number of currently available antineoplastic agents (Zwelling et al., 1987; Osheroff, 1989) .
Mammals possess two isoforms of topo II, termed ␣ (170 kDa) and ␤ (180 kDa), which have been mapped to human chromosomes 17q21-22 and 3p24, respectively (Tan et al., 1992) . They are highly homologous in the N-terminal threequarters (78% identity) but show lower homology in the Cterminal quarter (34% identity) (Austin et al., 1993) .
Topo II␣ and ␤ are differentially regulated during the cell cycle and are thought to carry out distinct cellular functions (Austin and Marsh, 1998 , and references therein). Levels of topo II␣ increase significantly during the S and G2/M phases of the cell cycle and subsequently decrease after mitosis (Heck et al., 1988; Prosperi et al., 1994) . Topo II␣ is therefore considered to be a specific marker for cellular proliferation, being required for chromosome condensation and segregation of intertwined daughter chromosomes (Heck and Earnshaw, 1986; Wang, 1996) . In contrast, levels of topo II␤ fluctuate less throughout the cell cycle; however, they are still cell cycle dependent (Prosperi et al., 1994; Meyer et al., 1997) . The cellular function of topo II␤ is as yet unknown.
Topo II is an important cellular target for a number of currently available chemotherapy agents (Zwelling et al., 1987; Osheroff, 1989) . These drugs inhibit the normal cellular function of topo II by stabilizing the usually transient "cleavable complex" that is formed during the catalytic cycle of the enzyme. Stabilized cleavable complexes are the primary lesions produced within the cell that initiate cell death. These are thought to be converted to permanent DNA breaks during DNA replication, causing various chromosomal aberrations (Pommier et al., 1985a; Chen et al., 1996; Suzuki et al., 1997) .
Studies of drug-resistant cell lines have revealed a number of factors responsible for cellular resistance to topo II inhibitors. Classical multidrug resistance, caused by overexpression of genes encoding multidrug resistance protein 1 and multidrug resistance-associated protein leads to increased efflux of exogenous toxins, including topo II inhibitors, from the cell, thereby reducing their cytotoxicity (Long et al., 1991; Lorico et al., 1995) . In addition, reduced levels of topo II and genetic mutations have been identified in various drug-resistant cell lines. Further investigations of sensitive and resistant cell lines have indicated that topo II␣ and ␤ may be differentially targeted by topo II agents (Mirski et al., 1993; Dereuddre et al., 1995) .
Levels of topo II␣ and ␤ in neoplastic tissues can vary between tumor types (Giaccone et al., 1995) . Cycling tumors contain higher levels of topo II␣ than tumors with a low percentage of cycling cells, and slow-growing tumors contain significant levels of topo II␤. It also has been reported that levels of topo II␤ are increased in human tumors compared with normal tissues (Turley et al., 1997) . Furthermore, lymphomas and breast cancers have been shown to contain predominately more topo II␣ than ␤, whereas seminomas contain equal levels of each isoform (Holden et al., 1992) . Therefore, levels of topo II␣ and ␤ in cancerous tissues and the specificity of topo II inhibitors are important factors to consider when trying to make regimes for cancer chemotherapy more selective. This paper investigates whether topo II␣ and ␤ are differentially targeted in vivo by several topo II inhibitors. Murine cell lines totally lacking topo II␤ have been used to assess the importance of topo II␣ and ␤ in the cytotoxic effects of etoposide, mitoxantrone, and three acridine derivatives, including amsacrine (mAMSA).
Materials and Methods

Construction of Murine Cell Lines
Targeted replacement of two exons of the murine TOP2␤ gene, one of which contains the codon for the active site tyrosyl residue of the enzyme, with a neomycin-resistance marker was carried out following standard protocols (W.L. and J.C. Wang, unpublished data). Heterozygous TOP2␤ ϩ/Ϫ mice were intercrossed and stage 13.5 embryos genotyped. A TOP2␤ ϩ/ϩ and a top2␤ Ϫ/Ϫ embryo were selected and used in the preparation of fibroblasts. Construction of immortalized fibroblasts, with simian virus 40 transformation, will be described elsewhere (L.L., W.L., and G.L., unpublished data).
Cell Culture
Murine topo II␤ Ϫ/Ϫ cell lines (mtop2␤-5 and mtop2␤-6) and a wild-type topo II␤ ϩ/ϩ cell line (mTOP2␤-4) were grown as monolayers at 37°C in a humidified atmosphere containing 5% CO 2 . These were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin (50 g/ml)/streptomycin (50 g/ml). Cell culture reagents were obtained from Gibco BRL, Paisley, UK. Cells were tested for Mycoplasma and were found to be free of contamination.
Whole-Cell Extracts
Whole-cell extracts were carried out as described by Mirski et al. (1993) . Briefly, cells were seeded at ϳ2.5 ϫ 10 5 cells/9-cm plate and left for 48 h to ensure the cells were growing exponentially. Cells were then scraped into 1 ml of ice-cold PBS and centrifuged at 1000g for 3 min. Cells were subsequently resuspended in four packed cell volumes of solution containing 0.25% SDS, 0.5 mg/ml deoxyribonuclease I, 0.25 mg/ml ribonuclease A, 10 mM MgCl, 50 mM Tris-HCl (pH 7.4) plus protease inhibitors (4 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 50 g/ml leupeptin, 1 g/ml pepstatin, and 2 g/ml aprotinin) and left on ice for 1 h. Proteins were then solublized by heating for 10 min at 68°C in 2% SDS, 10% glycerol, 5% ␤-mercaptoethanol, and 0.6 M Tris-HCl (pH7.5). Protein concentrations were subsequently estimated with the Bradford assay (Harlow and Lane, 1988) .
Western Blotting
Proteins from whole-cell extracts of mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells were electrophoresed (40 g of protein/lane) on 5% SDS polyacrylamide gels and transferred to a nitrocellulose filter by standard protocols. For detection of topo II␣ and ␤, blots were incubated with isoform specific antitopo II polyclonal antibodies, 18511(␣) or 18513(␤). They were used at 1:200 and 1:500 dilutions, respectively. The nitrocellulose filter was processed with the enhanced chemiluminescence detection kit (Amersham Corp., Amersham, UK) following the manufacturer's instructions.
Clonogenic Assay
Murine topo II␤ ϩ/ϩ (mTOP2-␤4) and topo II␤ Ϫ/Ϫ (mtop2␤-5 or mtop2␤-6) cells were seeded (2.5 ϫ 10 5 /plate) into 9-cm plates. After 48 h, drug was added to exponentially growing cells at appropriate concentrations for 2 h. The clonogenic assay was carried out as described previously in Moses et al. (1988) . Etoposide, mitoxantrone, and mAMSA were obtained from Sigma Chemical Co. (Poole, Dorset, UK). AMCA and mAMCA (analogs of mAMSA) were a gift from Dr. B. Baguley (University of Auckland School of Medicine, Private Bag 92019, Auckland, New Zealand).
Assay of Drug-Stabilized DNA Topo II-DNA Complexes
Preparation of Slides. The slide preparation method is described in detail by Willmore et al. (1998) . Briefly, cells were seeded (3 ϫ 10 4 cells/well) into six-well tissue culture plates. These were grown for ϳ48 h and drug was added to exponentially growing cells at appropriate concentrations. Microscope slides were precoated with agarose, and drug-treated or control (untreated) cells were immediately embedded in agarose and spread onto the slide. Slides were then placed in lysis buffer containing protease inhibitors for 30 min (after this stage slides could be stored at Ϫ20°C in PBS containing 10% glycerol), followed by 30 min in 1 M NaCl plus protease inhibitors. Slides were then washed three times in PBS (5 min/wash) and exposed to primary antisera for 1 to 2 h. Two antitopo II polyclonal antibodies, 18511(␣) and 18513(␤), were used. These antibodies were specific for the ␣-and ␤-isoforms of topo II, respectively. Both antibodies were used at a 1:50 dilution in PBS containing 0.1% v/v Tween 20 and 1% w/v BSA. Slides were washed three times in PBS containing 0.1% Tween 20 (PBST) and subsequently exposed for 1 to 2 h to a secondary antibody [anti-rabbit fluorescein isothiocyanate (FITC)-conjugated secondary antibody, F(abЈ) 2 fragment; Sigma] diluted in PBST containing 1% w/v BSA. Slides were washed three times in PBST followed by an overnight wash in PBS containing protease inhibitors, at 4°C.
Quantification of Cleavable Complexes. Slides were stained with Hoechst 33258 (10 M in PBS; Sigma Chemical Co.) for 5 min and cover slips were applied and secured. Images of blue (Hoechststained DNA) fluorescence and green (FITC-stained drug-stabilized topo II) immunofluorescence were then captured with an epifluorescence microscope attached to a cooled slow scan charge-coupled device camera. For each of eight randomly chosen fields of view, images of blue and green fluorescence were captured to give a total of ϳ100 cells/dose for each antibody.
Images were then analyzed to quantify the levels of Hoechst (blue) fluorescence and FITC (green) immunofluorescence with Imager 2 software (Astrocam, Cambridge, UK) based on Visilog 4 (Noesis, Paris, France). All images were corrected for stray light and camera background. Additionally, images were subjected to blue and green shade correction to compensate for variation in intensity of illumination and nonuniformities in light transmission (Willmore et al., 1998 , and reference therein). Statistical analysis was carried out using GraphPad Prism software (Cherwell Scientific, Oxford, UK). Paired t tests, repeated measures one-way ANOVA (Tukey post test), and two-way ANOVA were the main forms of analysis used for statistical comparisons.
Results
Levels of Topo II␣ and ␤. Western blot analysis confirmed that murine topo II␤ Ϫ/Ϫ cells (mtop2␤-5 and mtop2␤-6) did not contain any topo II␤. Figure 1a illustrates levels of topo II␤ found in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after the nitrocellulose filter was probed with 18513(␤). A 180-kDa band was identified in mTOP2␤-4 whole-cell extracts but was absent from the mtop2␤-5 and mtop2␤-6 whole-cell extracts, clearly illustrating that only mTOP2␤-4 cells contain topo II␤. Levels of topo II␣ in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells also were investigated (Fig. 1b) . Staining with 18511(␣) identified a 170-kDa band of similar intensity in each whole-cell extract, indicating that they contained similar levels of topo II␣.
Cell Line Characteristics. The doubling time of mTOP2␤ 4, mtop2␤-5, and mtop2␤-6 cells was 16 to 20 h for all three cell lines with no obvious difference between them. In addition, all three cell lines grow in elongated fashion and spread over the tissue culture plate; however, mtop2␤-6 cells appear to be slightly larger. Preliminary investigations suggest that there is no obvious difference in the cell cycle distribution of each cell line.
Sensitivity of Murine Topo II␤ ؉/؉ and Murine Topo II␤ ؊/؊ Cells to Topo II Inhibitors. Clonogenic assays were carried out to examine the cytotoxicity of etoposide, mitoxantrone, and the three acridine derivatives mAMSA, AMCA, and mAMCA on mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells to determine whether the absence of topo II␤ caused drug resistance. Initially, both mtop2␤-5 and mtop2␤-6 cells were used, however, both cell lines gave similar results so in subsequent experiments only mtop2␤-5 cells were used. Figure 2 , a and b compare the survival of topo II␤ ϩ/ϩ and topo II␤ Ϫ/Ϫ cells after exposure to a range of etoposide concentrations. IC 50 values of mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cell lines were 1.7 Ϯ 0.8, 2.1 Ϯ 1.4, and 1.1 Ϯ 1.0 M, respectively. Student's t test comparing mTOP2␤-4/ mtop2␤-5 and mTOP2␤-4/mtop2␤-6 IC 50 values indicated that there was no significant difference in the sensitivity of mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells to etoposide at the IC 50 . This also was confirmed with two-way ANOVA. However, at high doses of etoposide (i.e., Ͼ10 M) mtop2␤-5 and mtop2␤-6 cell survival was greater than observed for mTOP2␤-4 cells, although this difference was not statistically significant (t test). For example, for cell line mtop2␤-6 compared with mTOP2␤-4, the p values at 20 and 50 M were p ϭ .1285 and p ϭ .1143, respectively. Figure 2c shows the survival of mTOP2␤-4 and mtop2␤-5 cells after exposure to a range of mitoxantrone concentrations. This cytotoxicity data indicate that mtop2␤-5 cells were less sensitive than mTOP2␤-4 cells at high concentrations. Statistical analysis (t test) comparing the IC 50 values of mTOP2␤-4 and mtop2␤-5 cell lines (4.9 Ϯ 4.0 and 5.2 Ϯ 3.5 nM, respectively) indicated that both cell lines were equally sensitive to mitoxantrone, also confirmed with two-way ANOVA. However, the difference in mTOP2␤-4 and mtop2␤-5 cell survival at 50 nM was statistically significant (p ϭ .0449; t test), indicating that topo II␤ Ϫ/Ϫ cells (mtop2␤-5) were more resistant to mitoxantrone than wildtype topo II␤ ϩ/ϩ cells (mTOP2␤-4) at this concentration.
The cytotoxic effects of mAMSA, AMCA, and mAMCA on mTOP2␤-4 and mtop2␤-5 cells are illustrated in Fig. 2, d-f , respectively. Each of these graphs follows a similar trend, the percentage of mtop2␤-5 cells surviving is greater than mTOP2␤-4 cells over the full range of drug concentrations used. IC 50 values of mTOP2␤-4 and mtop2␤-5 cells were 0.06 Ϯ 0.01 and 0.08 Ϯ 0.03 M (mAMSA), 0.33 Ϯ 0.05 and 0.57 Ϯ 0.18 M (AMCA), and 0.34 Ϯ 0.2 and 0.7 Ϯ 0.3 M (mAMCA), respectively. Two-way ANOVA was used to compare the survival of mTOP2␤-4 and mtop2␤-5 cells after treatment with mAMSA, AMCA, and mAMCA, and this test confirmed that mtop2␤-5 cells were significantly more drug resistant than wild-type mTOP2␤-4 cells (p ϭ .0014, .0005, and .0034, respectively).
These data show that the sensitivity of topo II␤ Ϫ/Ϫ cells to etoposide was equivalent to that of the wild-type cells at lower drug concentrations. However, the topo II␤ Ϫ/Ϫ cells were significantly more resistant to mitoxantrone (at higher concentrations), mAMSA, AMCA, and mAMCA.
Quantification of Cleavable Complexes in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 Cells. The trapped in agarose DNA immunostaining (TARDIS) assay (Willmore et al., 1998) was used to quantify levels of drug-stabilized topo II␣ and ␤ cleavable complexes in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells. The assay involved embedding control (i.e., untreated cells) or drug-treated cells in agarose on microscope slides. The cells were then lysed to disrupt the cellular membranes and remove soluble proteins. After this, salt extraction was used to remove nuclear proteins and any noncovalently bound topo II from the DNA matrix. Drugstabilized topo II␣/␤-DNA complexes remained and were detected by staining with isoform specific antisera, either 18511(␣) or 18513(␤), followed by an FITC-conjugated secondary antibody. Digital images of Hoechst (DNA) fluorescence and FITC immunofluorescence (drug-stabilized topo II␣/␤ cleavable complexes) were captured and levels of fluorescence were quantified.
Figures 3 to 5 show the results of TARDIS experiments to measure topo II␣ and ␤ cleavable complexes in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after exposure to etoposide, mitoxantrone, and mAMSA, respectively. Figure 3 illustrates mean Hoechst fluorescence (a and c) and immunofluorescence (b and d) values from mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after a 2-h exposure to 0, 10, and 100 M etoposide. As illustrated in Fig. 3 , a and c, there was a slight increase in Hoechst fluorescence in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells with increasing concentrations of etoposide as reported previously for human leukemic CCRF-CEM cells (Willmore et al., 1998 ).
An etoposide dose-dependent increase in FITC immunofluorescence in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after staining with 18511(␣) is illustrated in Fig. 3b . The increase observed between 0 and 100 M in each cell line was signif- icant (all p values Ͻ .01). These results confirmed that etoposide-topo II␣-stabilized cleavable complexes were formed in all three cell lines. Figure 3d shows the levels of FITC immunofluorescence from mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after probing with 18513(␤). As illustrated, etoposide induces a clear dose-dependent increase in FITC immunofluorescence in mTOP2␤-4 cells that was highly significant at 100 M (p Ͻ .001). In contrast, the topo II␤ Ϫ/Ϫ cells (mtop2␤-5 and mtop2␤-6) showed no clear increase in FITC immunofluorescence with increasing concentrations of etoposide. Figure 4 , a and d show Hoechst fluorescence for mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after treatment with mitoxantrone. mTOP2␤-4 cells showed higher levels of Hoechst staining than mtop2␤-5 or mtop2␤-6 cells in control and drug-treated cells. Also, a slight increase in Hoechst fluorescence was observed between untreated and drugtreated cells, as seen with etoposide (Willmore et al., 1998) .
A mitoxantrone dose-dependent increase in FITC immunofluorescence in mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells was observed after staining with 18511(␣) (Fig. 4, b and c) . The difference between 0 to 1 and 0 to 10 M was significant for all cell lines (all p values Ͻ .05). There was no further increase in 18511(␣) immunofluorescence between 1 and 10 M mitoxantrone in mTOP2␤-4 and mtop2␤-5 cells (Fig. 4b) ; in fact, a slight decrease was observed. On further investigation, it was determined that if concentrations were raised to 100 M there was a further decrease in immunofluorescence, to approximately 2.5 ϫ 10 4 fluorescence units (data not shown). In addition, Fig. 4b demonstrates that at 10 M mitoxantrone mTOP2␤-4 cells had significantly higher levels of 18511(␣) immunofluorescence than mtop2␤-5 cells (p ϭ .0317). In contrast, the plateau in immunofluorescence and the reduction in 18511(␣) immunofluorescence in topo II␤ Ϫ/Ϫ cells was not observed in mtop2␤-6 cells (Fig. 4c) . Figure 4 , e and f illustrate the levels of FITC immunofluorescence from mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after staining with 18513(␤). There was a dose-dependent increase that was significant from 0 to 1 and 0 to 10 M mitoxantrone (both p values Ͻ .05) in mTOP2␤-4 cells. Levels of immunofluorescence plateau between 1 and 10 M (Fig.  4e) . In contrast, there was no increase in immunofluorescence in topo II␤ Ϫ/Ϫ (mtop2␤-5 and mtop2␤-6) cells, as expected. Figure 5 illustrates Hoechst and FITC immunofluorescence after treatment with mAMSA. Figure 5 , a and c, show that mTOP2␤-4 cells generally have higher levels of Hoechst staining than mtop2␤-5 and mtop2␤-6 cells. In addition, levels of Hoechst fluorescence, in each cell line, increase in drug-treated cells compared with untreated controls.
The mean immunofluorescence values from mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells after staining with 18511(␣) illustrates a dose-dependent increase for each cell line (Fig.  5b) . Furthermore, Fig. 5d shows a dose-dependent increase in 18513(␤) immunofluorescence in mTOP2␤-4 cells between 0.5, 5, and 50 M mAMSA with a slight decrease at 100 M. 
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The increase is highly significant from 0 to 100 M (p ϭ .0094; t test). In contrast, there is no significant increase in 18513(␤) FITC immunofluorescence in mtop2␤-5 and mtop2␤-6 cells.
Discussion
Homozygous topo II␤ Ϫ/Ϫ cells (mtop2␤-5 and mtop2␤-6) and wild-type control cells (mTOP2␤-4) have been exploited to assess the importance of topo II␣ and ␤ in the cytotoxic effects of five topo II inhibitors. Our results show that in mTOP2␤-4 cells, both topo II␣-and ␤-stabilized cleavable complexes are formed after treatment with etoposide, mitoxantrone, and mAMSA. In addition, they suggest that topo II␤ is important for the cytotoxic action of the acridine derivatives mAMSA, AMCA, and mAMCA and the anthraquinone mitoxantrone.
Quantification of etoposide-induced topo II␣-and ␤-cleavable complexes in mTOP2␤-4 cells indicated that both isoforms are in vivo targets for etoposide. These studies confirm data obtained from earlier investigations on CCRF-CEM human leukemic cells (with the same assay) that showed that both isoforms formed etoposide-stabilized cleavable complexes in vivo (Willmore et al., 1998) . In vitro data (Austin et al., 1995; Perrin et al., 1998) and yeast complementation studies (Meczes et al., 1997 ) also have implicated both topo II␣ and ␤ as possible targets for etoposide. In contrast, cytotoxicity data presented herein suggest that topo II␤ is probably not the major cytotoxic target for etoposide. This is in agreement with previous data, which have implicated topo II␣ as the main target of etoposide. For example, mutations and down-regulation of topo II␣, in vivo, leads to increased resistance (Feldoff et al., 1994; Mirski and Cole, 1995; Son et al., 1998) .
At high concentrations of mitoxantrone and mAMSA, levels of 18511(␣) and 18513(␤) immunofluorescence reach a plateau, suggesting that the level of cleavable complexes had reached saturation. However, this could have resulted from suppression of topo II activity at high drug concentrations. Both drugs are DNA intercalators and at low concentrations they intercalate into the DNA and stabilize topo II-DNA complexes. At higher concentrations, it has been reported that suppression of topo II function occurs that could prevent the formation of drug-stabilized cleavable complexes (Pommier, 1997) . It is therefore possible that the reduction in immunofluorescence at the highest doses was due to the topo II-suppressing activity of DNA intercalators.
Cytotoxicity studies have been used to assess the role of topo II␤ in inducing cell death. Figure 2c shows that topo II␤ Ϫ/Ϫ cells are resistant to mitoxantrone at high drug concentrations (50 nM), suggesting that topo II␤ is important for cytotoxicity. Our results confirm previous reports from in vitro (Perrin et al., 1998) and yeast complementation studies (Meczes et al., 1997) that also suggested that both isoforms were important for mitoxantrone cytotoxicity. Studies with sensitive and resistant cell lines have implicated a reduction of topo II␣ in mitoxantrone resistance (Son et al., 1998) . In contrast, topo II␤ has been implicated in mitoxantrone resistance, although this evidence was inconclusive because the resistant cells that lacked topo II␤ also contained altered topo II␣ (Harker et al., 1991 (Harker et al., , 1995 . Also, a cell line resistant to etoposide (due to cytoplasmic location of topo II␣) was not cross-resistant to mitoxantrone, suggesting that topo II␣ is not essential for mitoxantrone-induced cell death (Feldoff et al., 1994) . These previous studies are inconclusive. The isogenic cell lines used herein have the advantage that the only difference between topo II␤ ϩ/ϩ (mTOP2␤-4) and topo II␤ Ϫ/Ϫ (mtop2␤-5 and mtop2␤-6) cells is the loss of topo II␤ in the knockout cell lines. This is not the case with drug-resistant cell lines that have acquired resistance after drug exposure.
The mtop2␤-5 cells were considerably more resistant to acridine derivatives (mAMSA, AMCA, and mAMCA) than mTOP2␤-4 cells over a wide range of drug concentrations; therefore, topo II␤ is a significant cellular target for these compounds. However, although topo II␤ is an important target, it is not the only target because the mtop2␤-5 cells still undergo drug-induced cell death. The results presented herein verify previous in vitro work that demonstrated that mAMSA could induce cleavage with both isoforms (Austin et al., 1995) . In addition, chinese hamster lung cells resistant to 9-OH ellipticine that contained lower levels of topo II␣ and no topo II␤ were resistant to mAMSA. Transfection of topo II␤ into the resistant cells restored mAMSA sensitivity (Dereuddre et al., 1997) . Also, a GCL 4 cell line with reduced levels of topo II␤ and no alteration in topo II␣ was resistant to mAMSA (Withoff et al., 1996) . A recent report has suggested that reduced expression of TOP2␤ may contribute to mAMSA resistance (Herzog et al., 1998) . In contrast, two topo II␣ mutated cell lines were resistant to mAMSA (Lee et al., 1992) and expression of topo II␣ protein has been correlated to mAMSA sensitivity (Houlbrook et al., 1995) . Our TARDIS data, obtained with isogenic cell lines, shows that both isoforms are in vivo targets for mAMSA, and survival assays with topo II␤ Ϫ/Ϫ cells determined that topo II␤ is a significant target for cell killing.
The acridines AMCA and mAMCA are extremely toxic toward noncycling cells and it has been postulated that they might target topo II␤ because this isoform is predominant in nonproliferating cells (Baguely et al., 1997; Moreland et al., 1997) . Our results suggest that topo II␤ is targeted by both of these compounds in vivo. Interestingly, there is a reduction of topo II␣-cleavable complexes formed in mtop2␤-5 and mtop2␤-6 cells compared with wild-type mTOP2␤-4 cells at very high concentrations of mitoxantrone and mAMSA (Figs. 4b and 5b) . It could therefore be argued that resistance of mtop2␤-5 cells, demonstrated with cytotoxicity studies (Fig. 2, c and d) may not have been because of the absence of topo II␤ but rather because of a reduction in total number of ␣-and ␤-cleavable complexes. However, we do not think that this is the case for a number of reasons. First, a significant difference in the levels of FITC immunofluorescence was only observed at extremely high doses of mitoxantrone (ϳ2000-fold higher than IC 50 values obtained from clonogenic survival studies) when comparing mTOP2␤-4 and mtop2␤-5 cells. No statistically significant difference was seen for mAMSA at any of the drug doses. Second, topo II␤-mAMSA and mitoxantrone-stabilized cleavable complexes have been identified in vivo in mTOP2␤-4 cells. And third, mTOP2␤-4, mtop2␤-5, and mtop2␤-6 cells contain similar levels of topo II␣. We propose a hypothesis to explain the reduction in topo II␣ immunofluorescence in knockout cells at high drug concentrations. Topo II has the ability to alter DNA topology, therefore the absence of the ␤-isoform in topo II␤ Ϫ/Ϫ cells could cause these cells to have a different DNA conformation compared with that in the wild-type mTOP2␤-4 cells that contain both iso- forms. We observed that mtop2␤-5 and mtop2␤-6 cells consistently show less Hoechst staining than mTOP2␤-4 cells, particularly after drug treatment, suggesting that the DNA conformation was altered in the knockout cells. The difference in DNA conformation might alter the way drugs intercalate into the DNA at high concentration and affect the levels of topo II␣ drug-stabilized cleavable complexes in topo II␤ Ϫ/Ϫ cells compared with wild-type cells. We do not think that the reduction in topoII␣ cleavable complexes after treatment with high concentrations of mAMSA and mitoxantrone is responsible for the drug resistance of mtop2␤-5 cells. However, we cannot disregard this factor completely.
In conclusion, murine topo II␤ Ϫ/Ϫ cell lines have been used for the first time to investigate the role of topo II␤ in the cytotoxic action of several topo II inhibitors and to investigate the in vivo formation of topo II␣-and topo II␤-stabilized cleavable complexes. These studies confirm that both topo II␣-and ␤-stabilized cleavable complexes are formed in vivo after treatment with etoposide, mitoxantrone, and mAMSA, suggesting that both isoforms could be responsible for the cytotoxic effects of these compounds. Cytotoxicity studies, with these isogenic cell lines, have shown that topo II␤ does play a statistically significant role in the cytotoxic action of the three acridine derivatives investigated, mAMSA, AMCA, and mAMCA, and also the anthraquinone mitoxantrone.
